Canadian Generic Pharmaceutical Association (CGPA)
Specific Topics of Lobbying Communications | Intended Outcomes | Associated Subject Matters |
---|---|---|
Accelerating listing of generic drugs through regulatory reform.
|
Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity, Development or enactment of any regulation, including the enactment of a regulation for the purposes of amending or repealing a regulation
|
Health
|
Addressing and minimizing use of brand coupon cards.
|
Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity, Development or enactment of any regulation, including the enactment of a regulation for the purposes of amending or repealing a regulation
|
Health
|
Commencement of negotiations for Generics 3.0 Agreement with pan-Canadian Pharmaceutical Alliance
|
Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity
|
Health
|
Developing a regulatory pathway for biosimilars and increasing market share of biosimilar products in British Columbia.
|
Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity
|
Health
|
Discussions of British Columbia's position on the National Pharmacare initiative in a manner congruent with the interests of generic pharmaceutical manufacturers.
|
Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity
|
Health
|
Implementation of commitments made by British Columbia pursuant to its involvement with the pan-Canadian Pharmaceutical Alliance. Payment of distribution fees by the government.
|
Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity
|
Health
|
Improved demand forecasts and purchasing commitments from hospitals
|
Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity, Decision by the Executive Council or a member of the Executive Council to have the private sector instead of the Crown provide goods or services to the government of British Columbia or a Provincial entity
|
Health
|
Maintenance of bilateral meetings between the Ministry of Health and the CGPA.
|
Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity
|
Health
|
Measures to strengthen Canada's domestic pharmaceutical industry
|
Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity
|
Health
|
Payment of distribution fees by the government.
|
Awarding, amendment or termination of any contract, grant or financial benefit by or on behalf of the government of British Columbia or a Provincial entity, Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity
|
Health
|
Promoting greater utilization of generic prescription medicines.
|
Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity
|
Health
|
Protecting the interests of Canada's generic pharmaceutical industry during implementation of the Comprehensive Economic and Trade Agreement and the USMCA.
|
Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity
|
Health
|
Provincial government policy on opioid prescribing and dispensing and proper role of generic manufacturers.
|
Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity
|
Health
|